Calroy Health Sciences has launched Selentra HP, a hormone-free dietary supplement formulated to address symptoms across the perimenopause-to-postmenopause transition. The product centers on two researched active ingredients, positioning it within the evidence-adjacent tier of the women's hormonal wellness category — a segment drawing intensifying attention from both investors and mass-market retailers.
The menopause supplement market has expanded sharply as a wave of millennial and Gen X consumers moves into perimenopause and demands non-hormonal alternatives to hormone replacement therapy. Analysts tracking the broader women's health supplement space cite double-digit category growth, driven in part by heightened consumer awareness and a growing body of clinical literature on botanicals and nutraceutical compounds that may support vasomotor symptom management, mood stability, and sleep quality without exogenous hormone exposure.
Formulation & Positioning
Seletra HP's hormone-free architecture is a deliberate commercial and regulatory choice. Products that avoid hormone-derived or hormone-mimicking actives sidestep the more complex structure-function claim territory associated with phytoestrogens, while still allowing substantiated benefit language around comfort, balance, and symptom support. The dual-ingredient approach — while specific ingredient identities were not detailed in available materials — signals a combination-stack strategy common in premium finished formulations targeting a defined clinical endpoint, here the multi-phase menopause window from perimenopause through postmenopause.
For operators and contract manufacturers active in the women's health supplement space, Selentra HP's broad life-stage coverage is a notable formulation decision. Addressing peri- through postmenopause in a single SKU reduces consumer confusion at shelf and simplifies retail buyer conversations, compared with stage-segmented product lines that require shoppers to self-identify their hormonal phase.
Market & Retail Outlook
The menopause wellness category sits at the intersection of several high-velocity trends: the mainstreaming of women's hormonal health conversations, GLP-1-adjacent interest in metabolic wellness during midlife, and a broader consumer pivot toward functional and better-for-you supplements over pharmaceutical options where clinically appropriate. Retail buyers at natural and specialty channels have flagged menopause support as a priority shelf expansion area, and direct-to-consumer subscription models have shown strong retention in this demographic.
Calroy Health Sciences has not publicly disclosed retail distribution channels or pricing for Selentra HP at launch. As the category matures, clinical substantiation — including double-blind, placebo-controlled trial data on each active ingredient — will increasingly differentiate premium SKUs from commodity entries. Operators evaluating the menopause segment should monitor how brands like Calroy build their evidence dossiers, as retailer and practitioner channels are raising the bar on ingredient transparency and dose disclosure.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.